Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation

Longboard Pharmaceuticals received Rare Pediatric Disease and Orphan Drug Designations for bexicaserin, its treatment for Dravet syndrome, a rare and severe form of epilepsy. (September 19, 2024)

Source: Business Wire